International Guidelines and High-quality Standards for Treating Patients with GYN Cancers - Implementation in Low- and Middle-Income Countries

Cancer treatment guidelines are drafted to ensure appropriate use of existing evidence and promote safe practice. While guidelines strive to keep pace with research and new technology, they often don’t address the ground level situation in community practice especially for LMIC. Recent European quality indicators for radiotherapy of cervix cancer strive to recommend ideals for imaging, chemo and radiotherapies which may be difficult to meet even in resource constrained underserved areas of the U.S. - for e.g., 50-day treatment completion for >90% pts with cervix cancer. The development of molecular directed therapies for advanced endometrial cancers have out fringed the role of radiotherapy in practice and brought upfront costly immunotherapy regimens prematurely in the adjuvant setting resulting in dilemma for management in LMIC. Even modified pan-Asian guidelines look almost like their parent European guidelines raising questions about practical applicability. This activity addresses international quality measures and guidelines from providers in LMIC from three different continents. We also look at resource-constrained guidelines and ascertain applicability in different situation especially with a view to cervix and endometrial cancer. The expert panelists also look at new technology/alternative methods to meet these new quality standards and discuss methods they use in their practice to achieve optimal treatment for their patients. 

Topics:

  1. Implementing Radiation Guidelines for Endometrial Cancer in Resource-Constrained Regions: Insights from South America, Asia and Africa
    Sheynaz Bassa, MD, ChB
  2. Optimizing Cervical Cancer Brachytherapy - A Pragmatic Approach towards Resource Constraint Guidelines for LMIC/LIC Settings
    Umesh M. Mahantshetty, MD
  3. Hypofractionation for Locally Advanced Cervical Cancer: Current Evidence and Ongoing Trials
    Megan Kassick, MD, MPH
  4. Challenges of Meeting Guideline Determined Systemic Therapy Recommendations in Low- and Middle- Income Countries
    Nwamaka Lasebikan, MBBS, MSc., FWACS, FMCR

This activity is available from July 28, 2026, through 11:59 p.m. Eastern time on July 27, 2028. 

The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of radiation oncologists, physicists, nurses, radiation therapists, managers, global oncologists and residents.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Become familiar with recent changes in quality indicators and updates for cervix and endometrial cancer radiation and associated systemic therapies. 
  • Dissect the various resource constrained guidelines for these cancers.
  • Become updated on methods/techniques being utilized in LMIC to meet quality indicators like hypofractionation, auto-planning AI, and cheaper techniques for molecular analysis. 
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.
Course opens: 
07/28/2026
Course expires: 
07/27/2028
Cost:
$149.00
Rating: 
0

Moderator:  

  • Manjeet Chadha, MD, FASTRO, is employed by Icahn School of Medicine at Mount Sinai. Dr. Chadha has no relevant financial relationship with ineligible companies to disclose. 

Speakers:

  • Sheynaz Bassa, MD, ChB, is employed by Steve Biko Academic Hospital, University of Pretoria, South Africa. Dr. Bassa receives honoraria and travel expenses from MSD and Janssen Pharmaceuticals.   
  • Umesh M. Mahantshetty, MD, is employed by Homi Bhabha Cancer Hospital and Research Centre. Dr. Mahantshetty has no relevant financial relationship with ineligible companies to disclose.  
  • Megan Kassick, MD, MPH, is employed by Tufts University School of Medicine. Dr. Kassick has no relevant financial relationship with ineligible companies to disclose.  
  • Nwamaka Lasebikan, MBBS, MSc., FWACS, FMCR, is employed by National Institute for Cancer Research and Treatment NICRAT and the University of Nigeria Teaching Hospital Enugu. Dr. Lasebikan has no relevant financial relationship with ineligible companies to disclose.

Planners:

  • Malcolm Mattes, MD, is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies. 
  • Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies. 
  • Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
  • Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems. 
  • Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical. 

All relevant financial relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.25 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

  • Nonmember: $149
  • Member: $99
  • Member-in-Training: $49
  • Student/Graduate Student/PGY-1 Member: $49
  • Postdoctoral Fellow Member: $49

If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date. 

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until July 27, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date. 

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.